BioLineRx Ltd. ADR (BLRX)
NASDAQ: BLRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BLRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.80M
- EPS (TTM)
- $0.00
- Dividend yield
- None
- 52-week range
- 0.78 – 3.95
- Day range
- 0.78 – 1.10
- Volume / Avg
- 38.77K / 23.43K
- Beta
- —
- Shares outstanding
- 4.98M
- Next earnings
- Nov 23, 2026
52-week range
BLRX stock today
BioLineRx (BLRX) closed at $0.9639 on Nov 20, down 8.20% (-$0.0861), versus the S&P 500's 3.70% decline. At this level, BLRX sits near the bottom of its 52-week range of $0.78 to $3.95: 75.6% below the high, set on May 29, 2026 and 23.6% above the low. BLRX is down 65.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 70.3%.
BioLineRx has posted a net loss over the last twelve months (EPS of $0.00), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Nov 23 before the market opens; analysts expect EPS of -$0.38.
Summary generated from market data by MetaCap's automated system. Methodology
About BioLineRx
Company profileBioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Headquarters
- Hevel Modi'in
- Employees
- 20
- Website
- biolinerx.com
Financial highlights
Full financialsIn fiscal 2025, BioLineRx generated $1.2 million in revenue, down 95.9% from fiscal 2024, the first decline in the 11 years shown. BioLineRx reported a net loss of $2.0 million, compared with a loss of $9.2 million a year earlier. Gross margin was 80.5% (up from 68.0%) and operating margin -871.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.18M | $28.94M | $4.80M | $0 | $0 |
| Growth | -95.92% | +502.92% | — | — | — |
| Net income | $-2.03M | $-9.22M | $-60.61M | $-24.95M | $-27.05M |
| EPS (diluted) | $0.00 | $-0.01 | $-0.06 | $-0.03 | $-0.04 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$22.00+2182.39%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 23, 2026
- EPS estimate
- $-0.38
BLRX news
All BLRX newsBioLineRx peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PULMPulmatrix Inc. | 1.27 | -10.56% | $4.64M | vs BLRX |
| SNGXSoligenix Inc. | 0.2201 | -8.29% | $5.14M | vs BLRX |
| PCSAProcessa Pharmaceuticals Inc. | 1.56 | -7.69% | $4.37M | vs BLRX |
| CANFCan-Fite Biopharma Ltd ADR | 1.44 | -2.34% | $4.35M | vs BLRX |
| CNSPCNS Pharmaceuticals Inc. | 3.56 | -12.75% | $5.25M | vs BLRX |
| UPCUniverse Pharmaceuticals Inc. Class A | 1.08 | -20.59% | $5.43M | vs BLRX |
| TOVXTheriva Biologics Inc. | 0.12 | -6.25% | $5.51M | vs BLRX |
| SCNXScienture Holdings Inc. | 2.28 | -6.45% | $4.07M | vs BLRX |
Indexes, lists and sector
BioLineRx stock FAQ
What is BioLineRx's stock price today?
BLRX last traded at $0.9639 as of Nov 20, 4:00 PM EST, down 8.20% on the day. Prices are delayed at least 15 minutes.
Does BioLineRx pay a dividend?
No. BioLineRx does not currently pay a regular cash dividend.
When is BioLineRx's next earnings date?
BioLineRx is expected to report earnings on Monday, November 23, 2026. Analysts expect EPS of $-0.38.
Has BLRX ever split its stock?
Yes. The most recent BLRX stock split was a 1-for-40 split on Jan 30, 2025, one of 2 splits on record.
What is the BLRX 52-week high?
The 52-week high for BLRX is $3.95 and the 52-week low is $0.78. The stock is currently 75.6% below its high.